First Eagle Investment Management
TBPH icon

First Eagle Investment Management’s Theravance Biopharma TBPH Stock Holding History

First Eagle Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-455,330
Closed -$10.5M – 355
2014
Q3 		$10.5M Sell
455,330
-532
-0.1% -$15.4K 0.03% 167
2014
Q2 		$14.5M Buy
+455,862
New +$13.7M 0.04% 160

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Eagle Investment Management's TBPH Position: Q4 2014 in Review

First Eagle Investment Management sold out of Theravance Biopharma (TBPH) in Q4 2014, closing a stake of 455,330 shares — an estimated $10.5M sold.

First Eagle Investment Management first reported a position in TBPH in Q2 2014 and held it in 2 quarters. The position peaked at $14.5M in Q2 2014. 94 funds tracked by Wall St. Rank hold TBPH as of Q4 2014.

  • First Eagle Investment Management reported no remaining Theravance Biopharma position as of Q4 2014 after selling out during the quarter.
  • First Eagle Investment Management sold 455,330 Theravance Biopharma shares in Q4 2014, an estimated $10.5M.
  • First Eagle Investment Management first reported a position in Theravance Biopharma in Q2 2014 and held it in 2 quarters.
  • First Eagle Investment Management's Theravance Biopharma position peaked at $14.5M in Q2 2014.
  • 94 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2014.

Based on First Eagle Investment Management's 13F filing for Q4 2014, filed 9 Feb 2015.